Remineralized bone matrix as a scaffold for bone tissue engineering

Matthew A. Soicher, Blaine A Christiansen, Susan M Stover, Jonathan K Leach, Clare E Yellowley-genetos, Leigh G. Griffiths, David P Fyhrie

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is a need for improved biomaterials for use in treating non-healing bone defects. A number of natural and synthetic biomaterials have been used for the regeneration of bone tissue with mixed results. One approach is to modify native tissue via decellularization or other treatment for use as natural scaffolding for tissue repair. In this study, our goal was to improve on our previously published alternating solution immersion (ASI) method to fabricate a robust, biocompatible, and mechanically competent biomaterial from natural demineralized bone matrix (DBM). The improved method includes an antigen removal (AR) treatment step which improves mineralization and stiffness while removing unwanted proteins. The chemistry of the mineral in the remineralized bone matrix (RBM) was consistent with dicalcium phosphate dihydrate (brushite), a material used clinically in bone healing applications. Mass spectrometry identified proteins removed from the matrix with AR treatment to include a-2 HS-glycoprotein and osteopontin, noncollagenous proteins (NCPs) and known inhibitors of biomineralization. Additionally, the RBM supported the survival, proliferation, and differentiation of human mesenchymal stromal cells (MSCs) in vitro as well or better than other widely used biomaterials including DBM and PLG scaffolds. DNA content increased more than 10-fold on RBM compared to DBM and PLG; likewise, osteogenic gene expression was significantly increased after 1 and 2 weeks. We demonstrated that ASI remineralization has the capacity to fabricate mechanically stiff and biocompatible RBM, a suitable biomaterial for cell culture applications.

Original languageEnglish (US)
Pages (from-to)4480-4490
Number of pages11
JournalJournal of Biomedical Materials Research - Part A
Volume102
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Scaffolds (biology)
Tissue engineering
Bone
Biocompatible Materials
Biomaterials
Tissue
Antigens
Proteins
Tissue Scaffolds
Biomineralization
Glycoproteins
Osteopontin
Cell culture
Gene expression
Scaffolds
Minerals
Mass spectrometry
Phosphates
DNA
Repair

Keywords

  • Bone graft
  • Brushite
  • Collagen
  • Matrix
  • Mineralization
  • MSCs

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Ceramics and Composites
  • Metals and Alloys

Cite this

Remineralized bone matrix as a scaffold for bone tissue engineering. / Soicher, Matthew A.; Christiansen, Blaine A; Stover, Susan M; Leach, Jonathan K; Yellowley-genetos, Clare E; Griffiths, Leigh G.; Fyhrie, David P.

In: Journal of Biomedical Materials Research - Part A, Vol. 102, No. 12, 01.12.2014, p. 4480-4490.

Research output: Contribution to journalArticle

@article{4684916bc200440087cd28d9549c7787,
title = "Remineralized bone matrix as a scaffold for bone tissue engineering",
abstract = "There is a need for improved biomaterials for use in treating non-healing bone defects. A number of natural and synthetic biomaterials have been used for the regeneration of bone tissue with mixed results. One approach is to modify native tissue via decellularization or other treatment for use as natural scaffolding for tissue repair. In this study, our goal was to improve on our previously published alternating solution immersion (ASI) method to fabricate a robust, biocompatible, and mechanically competent biomaterial from natural demineralized bone matrix (DBM). The improved method includes an antigen removal (AR) treatment step which improves mineralization and stiffness while removing unwanted proteins. The chemistry of the mineral in the remineralized bone matrix (RBM) was consistent with dicalcium phosphate dihydrate (brushite), a material used clinically in bone healing applications. Mass spectrometry identified proteins removed from the matrix with AR treatment to include a-2 HS-glycoprotein and osteopontin, noncollagenous proteins (NCPs) and known inhibitors of biomineralization. Additionally, the RBM supported the survival, proliferation, and differentiation of human mesenchymal stromal cells (MSCs) in vitro as well or better than other widely used biomaterials including DBM and PLG scaffolds. DNA content increased more than 10-fold on RBM compared to DBM and PLG; likewise, osteogenic gene expression was significantly increased after 1 and 2 weeks. We demonstrated that ASI remineralization has the capacity to fabricate mechanically stiff and biocompatible RBM, a suitable biomaterial for cell culture applications.",
keywords = "Bone graft, Brushite, Collagen, Matrix, Mineralization, MSCs",
author = "Soicher, {Matthew A.} and Christiansen, {Blaine A} and Stover, {Susan M} and Leach, {Jonathan K} and Yellowley-genetos, {Clare E} and Griffiths, {Leigh G.} and Fyhrie, {David P}",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/jbm.a.35118",
language = "English (US)",
volume = "102",
pages = "4480--4490",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "1549-3296",
publisher = "Heterocorporation",
number = "12",

}

TY - JOUR

T1 - Remineralized bone matrix as a scaffold for bone tissue engineering

AU - Soicher, Matthew A.

AU - Christiansen, Blaine A

AU - Stover, Susan M

AU - Leach, Jonathan K

AU - Yellowley-genetos, Clare E

AU - Griffiths, Leigh G.

AU - Fyhrie, David P

PY - 2014/12/1

Y1 - 2014/12/1

N2 - There is a need for improved biomaterials for use in treating non-healing bone defects. A number of natural and synthetic biomaterials have been used for the regeneration of bone tissue with mixed results. One approach is to modify native tissue via decellularization or other treatment for use as natural scaffolding for tissue repair. In this study, our goal was to improve on our previously published alternating solution immersion (ASI) method to fabricate a robust, biocompatible, and mechanically competent biomaterial from natural demineralized bone matrix (DBM). The improved method includes an antigen removal (AR) treatment step which improves mineralization and stiffness while removing unwanted proteins. The chemistry of the mineral in the remineralized bone matrix (RBM) was consistent with dicalcium phosphate dihydrate (brushite), a material used clinically in bone healing applications. Mass spectrometry identified proteins removed from the matrix with AR treatment to include a-2 HS-glycoprotein and osteopontin, noncollagenous proteins (NCPs) and known inhibitors of biomineralization. Additionally, the RBM supported the survival, proliferation, and differentiation of human mesenchymal stromal cells (MSCs) in vitro as well or better than other widely used biomaterials including DBM and PLG scaffolds. DNA content increased more than 10-fold on RBM compared to DBM and PLG; likewise, osteogenic gene expression was significantly increased after 1 and 2 weeks. We demonstrated that ASI remineralization has the capacity to fabricate mechanically stiff and biocompatible RBM, a suitable biomaterial for cell culture applications.

AB - There is a need for improved biomaterials for use in treating non-healing bone defects. A number of natural and synthetic biomaterials have been used for the regeneration of bone tissue with mixed results. One approach is to modify native tissue via decellularization or other treatment for use as natural scaffolding for tissue repair. In this study, our goal was to improve on our previously published alternating solution immersion (ASI) method to fabricate a robust, biocompatible, and mechanically competent biomaterial from natural demineralized bone matrix (DBM). The improved method includes an antigen removal (AR) treatment step which improves mineralization and stiffness while removing unwanted proteins. The chemistry of the mineral in the remineralized bone matrix (RBM) was consistent with dicalcium phosphate dihydrate (brushite), a material used clinically in bone healing applications. Mass spectrometry identified proteins removed from the matrix with AR treatment to include a-2 HS-glycoprotein and osteopontin, noncollagenous proteins (NCPs) and known inhibitors of biomineralization. Additionally, the RBM supported the survival, proliferation, and differentiation of human mesenchymal stromal cells (MSCs) in vitro as well or better than other widely used biomaterials including DBM and PLG scaffolds. DNA content increased more than 10-fold on RBM compared to DBM and PLG; likewise, osteogenic gene expression was significantly increased after 1 and 2 weeks. We demonstrated that ASI remineralization has the capacity to fabricate mechanically stiff and biocompatible RBM, a suitable biomaterial for cell culture applications.

KW - Bone graft

KW - Brushite

KW - Collagen

KW - Matrix

KW - Mineralization

KW - MSCs

UR - http://www.scopus.com/inward/record.url?scp=84911805332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911805332&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.35118

DO - 10.1002/jbm.a.35118

M3 - Article

C2 - 24616346

AN - SCOPUS:84911805332

VL - 102

SP - 4480

EP - 4490

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 1549-3296

IS - 12

ER -